Compare Recursion Pharmaceuticals Inc (RXRX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sibanye Stillwater Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Sibanye Stillwater Ltd trades at $10.64 (market cap $7.54B). The key difference: Sibanye Stillwater Ltd is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap, and Sibanye Stillwater Ltd pays a 2.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SBSW | |
|---|---|---|
Market Cap | $1.81B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $21.12 |
52-Week Low | $2.84 | $7.27 |
Enterprise Value | $1.33B | $9.19B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Sibanye Stillwater (SBSW) trades at $10.77, up 0.94% with a bullish technical signal. Despite negative profitability metrics, the stock shows attractive valuation with P/E of 4.76 and P/S of 0.94. Recent earnings misses contrast with improved cash flow projections for 2025. Analyst consensus is mixed with 42.9% buy ratings and $14.25 price target, suggesting 32% upside potential.
The stock presents a value opportunity with deep undervaluation but carries significant execution risk. Key catalysts include debt reduction initiatives and commodity price recovery, while persistent negative margins and volatile earnings remain concerns. Institutional sentiment leans cautiously optimistic given the substantial discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
